Cartesian Therapeutics' (RNAC) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday, Benzinga reports. They currently have a $54.00 price target on the stock. Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC reiterated a buy rating and set […]

Related Keywords

United States ,American ,Timothya Springer ,Hall Laurie ,Leerink Partnrs ,Cartesian Therapeutics Inc ,Sg Americas Securities ,American International Group Inc ,Delphi Financial Group Inc ,Needham Company ,Cartesian Therapeutics ,Free Report ,Get Free Report ,Director Timothy ,Lauriej Trustee ,International Group ,Financial Markets ,Delphi Financial Group ,Cartesian Therapeutics Daily ,